8-K: UpHealth Amends Executive Employment Agreements Amidst Delisting Proceedings

UpHealth, Inc. has entered into second amended employment agreements with its CEO and CFO, outlining new compensation structures and severance terms, while also navigating ongoing delisting from the NYSE.

Summary

• UpHealth, Inc. has filed an 8-K report detailing second amended employment agreements with CEO Martin S.A. Beck and CFO Jay Jennings.
• Martin Beck's new agreement includes an annual base salary of $425,000, a potential 100% annual bonus, and a $187,000 retention bonus if he remains employed through June 1, 2024.
• Beck also received a $300,000 deal-based bonus for the completion of the Sale of Cloudbreak.
• Beck is eligible for performance bonuses up to $1,000,000 over three years based on revenue targets, with a modified calculation for 2023 revenue.
• Jay Jennings' new agreement includes an annual base salary of $375,000, a potential 75% annual bonus, and a $205,000 retention bonus if he remains employed through June 1, 2024.
• Jennings is also eligible for performance bonuses up to $125,000 over three years based on revenue targets.
• Both agreements include severance packages with varying terms depending on the circumstances of termination, including potential acceleration of equity awards.
• The company is still undergoing delisting proceedings from the NYSE, with a hearing scheduled for April 17, 2024.

Sentiment

Score: 4

Explanation: The document is mixed. While it provides details on new executive agreements, the ongoing delisting proceedings and the move to over-the-counter trading are significant negatives. The financial incentives for executives are positive, but the overall situation is concerning.

Positives

• The new employment agreements provide clarity on executive compensation and incentives.
• The retention bonuses for both the CEO and CFO may help retain key personnel.
• The deal-based bonus for the CEO recognizes the completion of the Sale of Cloudbreak.
• The performance-based bonuses align executive compensation with company performance.

Negatives

• The company is still undergoing delisting proceedings from the NYSE, which is a significant negative.
• The company's stock is now trading over-the-counter, which typically indicates a higher risk.
• The modified revenue calculation for the CEO's 2023 bonus may raise questions about financial reporting consistency.

Risks

• The delisting from the NYSE could negatively impact investor confidence and the company's ability to raise capital.
• The company's financial performance may not meet the targets required for the executives to earn their full performance bonuses.
• The modified revenue calculation for the CEO's 2023 bonus could lead to future accounting issues.
• The company's ability to retain key personnel may be affected by the delisting and other challenges.

Future Outlook

The document outlines the terms of the new employment agreements and does not provide specific forward-looking statements about the company's future performance or financial guidance. However, the company is still undergoing delisting proceedings from the NYSE, with a hearing scheduled for April 17, 2024.

Management Comments

• The Board delegated to the Compensation Committee the determination of the final terms of the written CEO and CFO Employment Agreements.
• The Board will determine whether and to what extent the applicable targeted level of revenue was achieved for fiscal year 2023 for the CEO bonus.
• The Board will determine whether and to what extent the applicable targeted level of revenue is achieved for fiscal year 2024 for the CEO and CFO bonuses.

Industry Context

The announcement comes at a time when many companies are adjusting executive compensation packages to align with performance and retention goals. The delisting proceedings add a layer of complexity, as the company needs to ensure stability and leadership continuity during this challenging period. The sale of Cloudbreak is a significant event that has triggered a deal-based bonus for the CEO, indicating a strategic shift for the company.

Comparison to Industry Standards

• The base salaries for the CEO and CFO are within the range for similar roles in small to mid-sized public companies, but the specific bonus structures and severance packages are tailored to UpHealth's unique situation.
• The use of retention bonuses is a common practice to incentivize key executives to remain with the company during periods of uncertainty, such as the delisting process.
• The performance-based bonuses tied to revenue targets are a standard approach to align executive compensation with company performance, but the specific targets and metrics are not disclosed in detail.
• The severance packages are fairly standard, with variations based on the circumstances of termination, including change in control provisions.
• Comparable companies in the digital health space, such as Teladoc Health and Amwell, also use a mix of base salary, bonuses, and equity awards, but their specific compensation structures and severance terms may vary based on their size, stage of development, and financial performance.
• The delisting from the NYSE is a significant event that is not typical for most public companies, and it adds a layer of complexity to the company's compensation and retention strategies.

Management Changes

Legal Proceedings

• The company is undergoing delisting proceedings from the NYSE, with a hearing scheduled for April 17, 2024.

Stakeholder Impact

• Shareholders may be concerned about the delisting from the NYSE and the company's future prospects.
• Employees may be affected by the uncertainty surrounding the company's future and the potential for further changes.
• Customers and suppliers may be impacted by the company's financial situation and the potential for disruptions.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will proceed with the NYSE delisting hearing on April 17, 2024.
• The company will need to monitor its financial performance to determine the extent to which executives earn their performance bonuses.
• The company will need to ensure compliance with the terms of the new employment agreements.
• The company will need to continue to operate as a public company while trading over-the-counter.

Key Dates

Keywords

UpHealth, executive compensation, employment agreement, CEO, CFO, delisting, NYSE, retention bonus, performance bonus, severance, stock options, Cloudbreak